SCHEMBL25211166

SCHEMBL25211166

CC(C)(C)OC(=O)N=S(C)(=O)c1ccc(C(=O)Nc2cc(-c3ccc(F)cc3)ccc2NC(=O)OC(C)(C)C)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.43
HDAC1 Q13547 2/20 0.42
KMT2A Q03164 4/20 0.41
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 2/20 0.41
HSD17B10 Q99714 1/20 0.41
MMP8 P22894 4/20 0.41
MMP3 P08254 2/20 0.41
KCNQ4 P56696 1/20 0.40
KCNQ5 Q9NR82 1/20 0.40
HDAC2 Q92769 2/20 0.40
KCNMA1 Q12791 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
RORC P51449 2/20 0.39
STING1 Q86WV6 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25256259 1.00 CYP17A1 (0.43) CYP17A1HDAC1KMT2AALDH1A1KDM4E
SCHEMBL25255025 1.00 CYP17A1 (0.43) CYP17A1HDAC1KMT2AALDH1A1KDM4E
SCHEMBL25238529 0.92 CYP17A1 (0.43) CYP17A1HDAC1KMT2AKDM4EHDAC2
SCHEMBL25222429 0.92 CYP17A1 (0.45) CYP17A1HDAC1KMT2AALDH1A1KDM4E
SCHEMBL25210833 0.91 HPGD (0.44) CYP17A1HDAC1ALDH1A1LMNAHPGD
SCHEMBL25224060 0.91 CYP17A1 (0.39) CYP17A1HDAC1KMT2AALDH1A1KDM4E
SCHEMBL25214571 0.91 F10 (0.43) CYP17A1HDAC1KMT2AALDH1A1KDM4E
SCHEMBL25216121 0.90 KMT2A (0.41) CYP17A1HDAC1KMT2AALDH1A1KDM4E
SCHEMBL25219248 0.90 CYP17A1 (0.49) CYP17A1HDAC1ALDH1A1HDAC2
SCHEMBL25215978 0.90 HDAC1 (0.52) HDAC1KMT2AALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2025-05-01 US disclosed
EP-4441033-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-10-09 EP disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
WO-2023102162-A1 TGONOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-06-08 WO disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 US disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 US disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 CYP17A1 1294/4885HDAC1 1/4885KMT2A 110/4885
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 CYP17A1 657/4885HDAC1 1/4885KMT2A 97/4885
US-12043607-B2 HDAC inhibitors and therapeutic use thereof HDAC1, HDAC7, HDAC5 CYP17A1 657/4885HDAC1 1/4885KMT2A 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.